Related Experiment Videos

Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a

H H Huang1, Y Y Zhang, Q Y Xiu

  • 1Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China. huanghaihui@fudan.edu.cn

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|June 13, 2006
PubMed

Insights

Community-acquired pneumonia (CAP) in Shanghai is often caused by Haemophilus influenzae and atypical pathogens. Antimicrobial susceptibility testing guides effective empirical therapy for CAP, with ampicillin showing good efficacy against H. influenzae.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Clinical Medicine

Background:

  • Community-acquired pneumonia (CAP) poses a significant public health challenge globally.
  • Identifying causative pathogens and their antimicrobial resistance patterns is crucial for effective treatment strategies.

Purpose of the Study:

  • To identify the primary causative pathogens of CAP in Shanghai, China.
  • To assess the antimicrobial susceptibility of identified bacterial and atypical pathogens.
  • To inform empirical treatment guidelines for CAP in the Shanghai region.

Main Methods:

  • A multicenter study involving 389 patients with documented CAP between 2001 and 2003.
  • Pathogen identification using bacterial culture, polymerase chain reaction (PCR), and immunological assays.
  • Antimicrobial susceptibility testing performed via the broth microdilution method.

Main Results:

  • A specific pathogen was identified in 39.8% of patients.
  • Haemophilus influenzae (n=80) and atypical pathogens (Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila) were the most common.
  • Most H. influenzae isolates were susceptible to ampicillin (88.3%) and macrolides. Streptococcus pneumoniae isolates showed variable susceptibility to penicillin.

Conclusions:

  • H. influenzae and atypical pathogens are key etiological agents of CAP in Shanghai.
  • Ampicillin, cephalosporins, and fluoroquinolones are recommended for empirical CAP therapy in this region.
  • Further evaluation is needed for the efficacy of macrolide monotherapy against S. pneumoniae-related CAP.

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps: